Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review.

Coyle PK, Oh J, Magyari M, Oreja-Guevara C, Houtchens M.

Mult Scler Relat Disord. 2019 Jul;32:54-63. doi: 10.1016/j.msard.2019.04.003. Epub 2019 Apr 5. Review.

2.

Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study.

Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Poole EM, Robinson M, Gold R.

Mult Scler Relat Disord. 2019 Jun;31:157-164. doi: 10.1016/j.msard.2019.03.022. Epub 2019 Mar 30.

3.

Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.

Vukusic S, Coyle PK, Jurgensen S, Truffinet P, Benamor M, Afsar S, Purvis A, Poole EM, Chambers C.

Mult Scler. 2019 Apr 10:1352458519843055. doi: 10.1177/1352458519843055. [Epub ahead of print]

PMID:
30968734
4.

Central Nervous System Vasculitis due to Infection.

Younger DS, Coyle PK.

Neurol Clin. 2019 May;37(2):441-463. doi: 10.1016/j.ncl.2019.01.002. Epub 2019 Mar 16. Review.

PMID:
30952418
5.

Characterization of gray-matter multiple sclerosis lesions using double inversion recovery, diffusion, contrast-enhanced, and volumetric MRI.

Parra Corral MA, Govindarajan ST, Stefancin P, Bangiyev L, Coyle PK, Duong TQ.

Mult Scler Relat Disord. 2019 Jun;31:74-81. doi: 10.1016/j.msard.2019.03.021. Epub 2019 Mar 29.

PMID:
30951968
6.

Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.

Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Thangavelu K, Robinson M, Gold R; Teri-PRO Trial Group.

Mult Scler Relat Disord. 2018 Nov;26:211-218. doi: 10.1016/j.msard.2018.09.017. Epub 2018 Sep 15.

7.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.

N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.

8.

Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.

Coyle PK, Shang S, Xiao Z, Dong Q, Castrillo-Viguera C.

Mult Scler Relat Disord. 2018 May;22:134-138. doi: 10.1016/j.msard.2018.02.021. Epub 2018 Feb 18.

9.

Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database.

Sandberg-Wollheim M, Neudorfer O, Grinspan A, Weinstock-Guttman B, Haas J, Izquierdo G, Riley C, Ross AP, Baruch P, Drillman T, Coyle PK.

Int J MS Care. 2018 Jan-Feb;20(1):9-14. doi: 10.7224/1537-2073.2016-079.

10.

Fatigue and Mood States in Nursing Home and Nonambulatory Home-Based Patients with Multiple Sclerosis.

Younus Z, Vaughn CB, Sanai SA, Kavak KS, Gupta S, Nadeem M, Teter BE, Noyes K, Zivadinov R, Edwards K, Coyle PK, Goodman A, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

Int J MS Care. 2017 Nov-Dec;19(6):297-302. doi: 10.7224/1537-2073.2016-058.

11.

Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.

Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Brette S, Robinson M, Gold R; Teri-PRO Trial Group.

Mult Scler Relat Disord. 2017 Oct;17:107-115. doi: 10.1016/j.msard.2017.07.006. Epub 2017 Jul 6.

12.

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study.

Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, Vermersch P, Damian D, Dangond F.

Mult Scler J Exp Transl Clin. 2017 Oct 9;3(4):2055217317732802. doi: 10.1177/2055217317732802. eCollection 2017 Oct-Dec.

13.

Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives.

Coyle PK.

Mult Scler Int. 2017;2017:6198530. doi: 10.1155/2017/6198530. Epub 2017 Jul 19. Review.

14.

Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study.

Coyle PK, Reder AT, Freedman MS, Fang J, Dangond F.

J Neurol Sci. 2017 Aug 15;379:151-156. doi: 10.1016/j.jns.2017.05.052. Epub 2017 May 25.

15.

Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).

Zivadinov R, Cookfair DL, Krupp L, Miller AE, Lava N, Coyle PK, Goodman AD, Jubelt B, Lenihan M, Herbert J, Gottesman M, Snyder DH, Apatoff BR, Teter BE, Perel AB, Munschauer F, Weinstock-Guttman B.

BMC Neurol. 2016 Jul 15;16:102. doi: 10.1186/s12883-016-0623-2.

16.

Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?

Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S, Hass S, Coyle PK.

Mult Scler. 2017 Apr;23(4):604-613. doi: 10.1177/1352458516657441. Epub 2016 Jul 11.

17.

Symptom Management and Lifestyle Modifications in Multiple Sclerosis.

Coyle PK.

Continuum (Minneap Minn). 2016 Jun;22(3):815-36. doi: 10.1212/CON.0000000000000325. Review.

PMID:
27261684
18.

Management of women with multiple sclerosis through pregnancy and after childbirth.

Coyle PK.

Ther Adv Neurol Disord. 2016 May;9(3):198-210. doi: 10.1177/1756285616631897. Epub 2016 Mar 2. Review.

19.

Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.

Cohen BA, Coyle PK, Leist T, Oleen-Burkey MA, Schwartz M, Zwibel H.

Mult Scler Relat Disord. 2015 Jan;4(1):75-82. doi: 10.1016/j.msard.2014.09.214. Epub 2014 Oct 7.

PMID:
25787057
20.

Multiple sclerosis and pregnancy prescriptions.

Coyle PK.

Expert Opin Drug Saf. 2014 Dec;13(12):1565-8. doi: 10.1517/14740338.2014.973848.

PMID:
25406727
21.

Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.

Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N.

Adv Ther. 2014 Oct;31(10):1072-81. doi: 10.1007/s12325-014-0154-4. Epub 2014 Sep 23.

PMID:
25245812
22.

Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.

Coyle PK, Sinclair SM, Scheuerle AE, Thorp JM Jr, Albano JD, Rametta MJ.

BMJ Open. 2014 May 12;4(5):e004536. doi: 10.1136/bmjopen-2013-004536.

23.

Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes.

Coyle PK, Cohen BA, Leist T, Markowitz C, Oleen-Burkey M, Schwartz M, Tullman MJ, Zwibel H.

BMC Neurol. 2014 Mar 13;14:49. doi: 10.1186/1471-2377-14-49.

24.

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.

Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M; oral cladribine for early MS (ORACLE MS) Study Group.

Lancet Neurol. 2014 Mar;13(3):257-67. doi: 10.1016/S1474-4422(14)70005-5. Epub 2014 Feb 4.

PMID:
24502830
25.

Multiple sclerosis in pregnancy.

Coyle PK.

Continuum (Minneap Minn). 2014 Feb;20(1 Neurology of Pregnancy):42-59. doi: 10.1212/01.CON.0000443836.18131.c9. Review.

PMID:
24492810
26.

Current evaluation of alemtuzumab in multiple sclerosis.

Coyle PK.

Expert Opin Biol Ther. 2014 Jan;14(1):127-35. doi: 10.1517/14712598.2014.866084. Epub 2013 Dec 2.

PMID:
24289293
27.

Gray matter is targeted in first-attack multiple sclerosis.

Schutzer SE, Angel TE, Liu T, Schepmoes AA, Xie F, Bergquist J, Vécsei L, Zadori D, Camp DG 2nd, Holland BK, Smith RD, Coyle PK.

PLoS One. 2013 Sep 10;8(9):e66117. doi: 10.1371/journal.pone.0066117. eCollection 2013.

28.

Switching therapies in multiple sclerosis.

Coyle PK.

CNS Drugs. 2013 Apr;27(4):239-47. doi: 10.1007/s40263-013-0042-5.

PMID:
23508518
29.

X-ray microbeam irradiation of the contusion-injured rat spinal cord temporarily improves hind-limb function.

Dilmanian FA, Jenkins AL 3rd, Olschowka JA, Zhong Z, Park JY, Desnoyers NR, Sobotka S, Fois GR, Messina CR, Morales M, Hurley SD, Trojanczyk L, Ahmad S, Shahrabi N, Coyle PK, Meek AG, O'Banion MK.

Radiat Res. 2013 Jan;179(1):76-88. doi: 10.1667/RR2921.1. Epub 2012 Dec 5.

PMID:
23216524
30.

Pregnancy and multiple sclerosis.

Coyle PK.

Neurol Clin. 2012 Aug;30(3):877-88. doi: 10.1016/j.ncl.2012.05.002. Epub 2012 Jun 22. Review.

PMID:
22840794
31.

Interleaved carbon minibeams: an experimental radiosurgery method with clinical potential.

Dilmanian FA, Rusek A, Fois GR, Olschowka J, Desnoyers NR, Park JY, Dioszegi I, Dane B, Wang R, Tomasi D, Lee H, Hurley SD, Coyle PK, Meek AG, O'Banion MK.

Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):514-9. doi: 10.1016/j.ijrobp.2011.12.025. Epub 2012 Feb 17.

PMID:
22342299
32.

Dissecting the immune component of neurologic disorders: a grand challenge for the 21st century.

Coyle PK.

Front Neurol. 2011 Jun 6;2:37. doi: 10.3389/fneur.2011.00037. eCollection 2011. No abstract available.

33.

The changing face of multiple sclerosis clinical trial populations.

Uitdehaag BM, Barkhof F, Coyle PK, Gardner JD, Jeffery DR, Mikol DD.

Curr Med Res Opin. 2011 Aug;27(8):1529-37. doi: 10.1185/03007995.2011.591370. Epub 2011 Jun 15. Review.

PMID:
21671851
34.

Pediatric multiple sclerosis: just like their elders?

Coyle PK.

Arch Neurol. 2011 Apr;68(4):419-21. doi: 10.1001/archneurol.2011.49. No abstract available.

PMID:
21482921
35.

Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome.

Schutzer SE, Angel TE, Liu T, Schepmoes AA, Clauss TR, Adkins JN, Camp DG, Holland BK, Bergquist J, Coyle PK, Smith RD, Fallon BA, Natelson BH.

PLoS One. 2011 Feb 23;6(2):e17287. doi: 10.1371/journal.pone.0017287.

36.

Gender issues in multiple sclerosis: an update.

Jobin C, Larochelle C, Parpal H, Coyle PK, Duquette P.

Womens Health (Lond). 2010 Nov;6(6):797-820. doi: 10.2217/whe.10.69. Review.

PMID:
21118039
37.

The role of natalizumab in the treatment of multiple sclerosis.

Coyle PK.

Am J Manag Care. 2010 Jun;16(6 Suppl):S164-70. Review.

38.

Establishing the proteome of normal human cerebrospinal fluid.

Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA, Purvine SO, Hixson KK, Lipton MS, Camp DG, Coyle PK, Smith RD, Bergquist J.

PLoS One. 2010 Jun 11;5(6):e10980. doi: 10.1371/journal.pone.0010980.

39.

Disease-modifying agents in multiple sclerosis.

Coyle PK.

Ann Indian Acad Neurol. 2009 Oct;12(4):273-82. doi: 10.4103/0972-2327.58280.

40.

Early treatment of multiple sclerosis to prevent neurologic damage.

Coyle PK.

Neurology. 2008 Dec 9;71(24 Suppl 3):S3-7. doi: 10.1212/WNL.0b013e31818f3d6f.

PMID:
19064872
41.

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B; REGARD study group.

Lancet Neurol. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11.

PMID:
18789766
42.

Invited article: The ABPN maintenance of certification program for neurologists: past, present, and future.

Faulkner LR, Tivnan PW, Johnston MV, Aminoff MJ, Coyle PK, Crumrine PK, Dekosky ST, Jozefowicz R, Massey JM, Pascuzzi RM.

Neurology. 2008 Aug 19;71(8):599-604. doi: 10.1212/01.wnl.0000310815.29495.85. Epub 2008 Jul 2. No abstract available.

PMID:
18596242
43.

Switching algorithms: from one immunomodulatory agent to another.

Coyle PK.

J Neurol. 2008 Mar;255 Suppl 1:44-50. doi: 10.1007/s00415-008-1007-3. Review.

PMID:
18317676
44.

Proof-of-Principle to Measure Potassium in the Human Brain: A Feasibility Study.

Wielopolski L, Ramirez LM, Coyle PK, Wang ZM, Heymsfield SB.

Int J Body Compos Res. 2004;2(1):37-43.

45.

Evidence-based medicine and clinical trials.

Coyle PK.

Neurology. 2007 Jun 12;68(24 Suppl 4):S3-7. Review.

PMID:
17562847
46.

Relapses matter: the costs & consequences of multiple sclerosis relapses.

Coyle PK, Johnson KP.

J Neurol Sci. 2007 May 15;256 Suppl 1:S1-4. Epub 2007 Mar 9. Review. No abstract available.

PMID:
17350044
47.

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.

Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D; PROMiSe Trial Study Group.

Ann Neurol. 2007 Jan;61(1):14-24.

PMID:
17262850
48.

Survey of training programs' means for promoting neurology and attracting trainees.

Adair JC, Rudnicki SA, Boudreau E, Weiner WJ, Coyle PK, Corboy JR.

Neurology. 2006 Sep 26;67(6):936-9.

PMID:
17000957
49.

High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.

Gladstone DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Christodoulou C, Locher E, Coyle PK.

Arch Neurol. 2006 Oct;63(10):1388-93. Epub 2006 Aug 14.

PMID:
16908728
50.

Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.

Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, Frank JA, Grossman R, Paty DW, Radue EW, Wolinsky JS.

AJNR Am J Neuroradiol. 2006 Feb;27(2):455-61. No abstract available.

Supplemental Content

Loading ...
Support Center